DOJ shifts from criminal probe to civil recovery
The Justice Department has closed its criminal investigation into Abbott Laboratories’ handling of a Michigan infant formula plant and instead plans to seek civil penalties, the Wall Street Journal reported Sunday. Reuters said it couldn’t independently verify the report, and the department and Abbott didn’t immediately respond to requests for comment. That qualification matters: the reported change in direction hasn’t been confirmed by either party, and the details available so far come from the Journal’s account.
The reported decision ends a probe in which prosecutors considered misdemeanor charges against Abbott for allegedly violating the federal Food, Drug and Cosmetic Act and misleading the government. The WSJ also reported that prosecutors weighed charges against at least one individual. Some prosecutors believed the evidence supported charging the company, but senior decision makers chose another course, according to the report.
That difference in views, if accurately described, points to a familiar tension in corporate enforcement: investigators may see a basis for a case while senior officials weigh whether prosecution is the right way to address the alleged conduct. The report doesn’t explain the decision makers’ reasoning in detail, so it’s not possible to say which considerations proved decisive. The outcome does make one thing clear: the criminal inquiry is reportedly over, while the department is still pursuing a financial remedy.
What the proposed remedy would target
The alternative reportedly involves recovering money Abbott earned from formula sales through federally funded nutrition programs. A DOJ spokeswoman told the WSJ: “Ensuring the safety of our nation’s food supply is a top priority for the Trump administration; however, this Department of Justice does not believe in regulation by prosecution.”
A recovery tied to program sales would focus on the financial benefits identified in the report, rather than on a criminal conviction. The distinction is consequential. Criminal charges can carry a public finding of wrongdoing through the court process; a civil recovery can seek money without establishing the same criminal liability. The article doesn’t specify the amount sought, the legal basis for calculating it, or whether Abbott would contest such a claim.
The department’s quoted statement frames the choice as one about enforcement method. It says food safety remains a priority while rejecting prosecution as the preferred tool in this case. That position doesn’t settle the underlying allegations, and it doesn’t tell readers how the department would handle similar matters. The reported shift is narrower: officials are said to have chosen a civil path after considering criminal charges.
Recall and supply disruption
Abbott recalled infant formula and shut its Michigan plant in 2022 after investigators found traces of potentially deadly bacteria there. The closure and recall aggravated a nationwide formula shortage already strained by pandemic-related supply chain problems. The episode connected operational and product safety concerns with a material disruption to a tightly supplied market.
That combination made the case larger than a dispute about one plant. Infant formula is an essential product for families who rely on it, and a major production interruption can add pressure when supply is already constrained. The source doesn’t quantify the plant’s share of the market or the shortage’s duration, so those effects shouldn’t be overstated. Still, the reported history shows why decisions about safety controls and production continuity can carry consequences beyond a company’s own operations.
For businesses in similarly concentrated or time-sensitive supply chains, the episode is a reminder that an operational shutdown can have effects across the market. (And this is the part most people overlook.) A remedy focused on program sales addresses one financial dimension of the matter, but it doesn’t itself explain how future disruptions might be prevented or how responsibility for the episode was assessed.
Disputed allegations and the unresolved questions
Abbott said at the time that no evidence linked its formula to the illnesses. A company spokesman told the WSJ that no unopened, distributed Abbott formula had tested positive for the bacteria that sickened the babies. The reported shift from a criminal probe to civil recovery leaves the company facing a financial remedy tied to program sales, while the underlying allegations remain disputed.
Those statements describe Abbott’s position; they don’t establish what prosecutors concluded about the evidence. Nor does the reported decision to close the criminal investigation amount to a public resolution of every factual question surrounding the plant, the recall, or the government’s allegations. The available account leaves readers without the department’s explanation of its decision and without Abbott’s response to the latest report.
This is more significant than it looks. The change in enforcement route may shape how the public interprets accountability, but the information reported so far doesn’t support a firm conclusion about whether the company or any individual would have been convicted. If you’re working in this space, the practical point is that safety allegations, production interruptions, and government program sales can converge in a single enforcement matter.
What to watch next
The next useful details would be whether the Justice Department formally pursues civil recovery, what conduct and sales it says are covered, and how Abbott responds. None of those steps is established by the report itself. Until there’s confirmation, the proposed remedy should be treated as a reported plan, not a completed settlement or a final finding.
For now, the outcome appears to leave the criminal investigation behind while keeping a financial dispute in view. A civil path may resolve some questions about money, yet the public account still lacks the detail needed to judge the evidence, the internal decision, or the full consequences of the plant shutdown. That uncertainty is the story’s central limitation.